Listing 1 - 5 of 5 |
Sort by
|
Choose an application
"Tuberculosis is one of the leading causes of death in the world today, with 4,500 people dying from the disease every day. Many cases of TB can be cured by available antibiotics, but some TB is resistant to multiple drugs--a major and growing threat worldwide. The Institute of Medicine's Forum on Drug Discovery, Development, and Translation hosted a workshop on November 5, 2008, to address the mounting concern of drug-resistant TB. The session brought together a wide range of international experts to discuss what is known and not known about this growing threat, and to explore possible solutions."--Publisher's website.
Antitubercular agents -- Congresses. --- Drug resistance -- Congresses. --- Electronic books. -- local. --- Multidrug-resistant tuberculosis -- Congresses. --- Tuberculosis -- Congresses. --- Multidrug-resistant tuberculosis --- Tuberculosis --- Drug resistance --- Antitubercular agents --- Congresses --- Internationality --- HIV Infections --- Tuberculosis, Multidrug-Resistant --- Antitubercular Agents --- Anti-Bacterial Agents --- Publication Formats --- Sexually Transmitted Diseases, Viral --- Lentivirus Infections --- Social Sciences --- Immunologic Deficiency Syndromes --- Retroviridae Infections --- Mycobacterium Infections --- Publication Characteristics --- Anti-Infective Agents --- Immune System Diseases --- Anthropology, Education, Sociology and Social Phenomena --- Sexually Transmitted Diseases --- Virus Diseases --- Actinomycetales Infections --- RNA Virus Infections --- Diseases --- Therapeutic Uses --- Gram-Positive Bacterial Infections --- Pharmacologic Actions --- Chemical Actions and Uses --- Bacterial Infections --- Bacterial Infections and Mycoses --- Chemicals and Drugs --- Infectious Diseases --- Medicine --- Health & Biological Sciences --- Drugs, Antitubercular --- Tuberculostatic agents --- Resistance to drugs --- MDR-TB (Multidrug-resistant tuberculosis) --- MDR tuberculosis --- Polydrug-resistant tuberculosis --- Antibacterial agents --- Pharmacology --- Drug resistance in microorganisms --- Multidrug resistance --- Chemotherapy
Choose an application
Drugs --- Pharmaceutical biotechnology --- Technology, Pharmaceutical --- Pharmacy --- Investigative Techniques --- Technology --- Technology, Industry, and Agriculture --- Health Occupations --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Disciplines and Occupations --- Technology, Industry, Agriculture --- Pharmacy, Therapeutics, & Pharmacology --- Health & Biological Sciences --- Safety measures --- Design
Choose an application
"The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to explore innovative strategies for orphan drug development."--P. 3.
Orphan drugs --- Pharmaceutical policy --- Drugs --- Government policy --- Design
Choose an application
"An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise."--Publisher's description.
Clinical trials --- Chemistry, Pharmaceutical --- Evaluation Studies as Topic --- Epidemiologic Study Characteristics as Topic --- Social Control Policies --- North America --- Investigative Techniques --- Publication Formats --- Epidemiologic Methods --- Americas --- Policy --- Chemistry --- Publication Characteristics --- Pharmacology --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Social Control, Formal --- Health Care Evaluation Mechanisms --- Drug Discovery --- Public Policy --- Clinical Trials as Topic --- Congresses --- United States --- Health Care Economics and Organizations --- Public Health --- Geographic Locations --- Natural Science Disciplines --- Biological Science Disciplines --- Sociology --- Quality of Health Care --- Social Sciences --- Disciplines and Occupations --- Health Care --- Health Care Quality, Access, and Evaluation --- Geographicals --- Environment and Public Health --- Anthropology, Education, Sociology and Social Phenomena --- Medicine --- Health & Biological Sciences --- Medical Research --- Research --- Government policy
Choose an application
"Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held 'Assessing and Accelerating Development of Biomarkers for Drug Safety,' a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development."--Publisher's website.
Biochemical markers --- Drugs --- Safety measures --- Testing
Listing 1 - 5 of 5 |
Sort by
|